Sensydia

Developer of a portable, point-of-care hemodynamic measurement platform that uses proprietary sensor technology and machine learning to guide critical patient management decisions in heart failure, sepsis, pulmonary hypertension, and other critical diseases. The Sensydia Cardiac Performance System™ (CPS) is entirely non-invasive, trained to gold standard, and can be deployed in minutes in the hospital, clinic, office or at home. By making hemodynamic insights as accessible as routine blood pressure readings, CPS will enable early disease detection and improve disease management through accurate, easy-to-use, non-invasive monitoring.

Sensydia headquartered in United States, North America, operates in the Artificial Intelligence (AI), Wireless, Health Care, Medical Device, Wearables sector. The company focuses on Artificial Intelligence (AI) and has secured $2.1B in funding across 100 round(s). With a team of 1-10 employees, Sensydia is actively contributing to advancements in Artificial Intelligence (AI). Their latest funding round, Grant - Sensydia, raised $3.0M. Discover more about their projects, partnerships, and impact on our platform.